{"id":"W2117355364","doi":"10.1016/s1470-2045(15)00216-8","title":"Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; Internal medicine; Colorectal cancer; Maintenance therapy; Oncology; Clinical endpoint; Progression-free survival; Chemotherapy; Cancer; Randomized controlled trial; Surgery; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007586781,0.0003902151,0.001818992,0.0000798969,0.0001411572,0.00004708152,0.0003709925,0.0000799561,0.0001982523],"category_scores_gemma":[0.0001840466,0.0001680052,0.00004380916,0.0004256167,0.000376237,0.0001433522,0.0001173436,0.0003455381,0.00001715166],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007686729,"about_ca_system_score_gemma":0.001737527,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001422518,"about_ca_topic_score_gemma":0.006025941,"domain_scores_codex":[0.9976246,0.0003829064,0.0004329277,0.0005003011,0.0004165461,0.0006426641],"domain_scores_gemma":[0.9984393,0.0003403587,0.0003207849,0.0003778155,0.0003261165,0.000195612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9516242,0.004246344,0.01513744,0.00001810367,0.000946502,0.0002280444,0.002883192,0.0000130167,0.00001585918,0.00003871887,0.00232527,0.02252329],"study_design_scores_gemma":[0.8869565,0.09640283,0.004646573,0.0001342681,0.0004026437,0.00007897777,0.0007628187,0.00009075761,0.00007667091,0.00005223793,0.01013407,0.0002616444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819165,0.0004649067,0.00001219886,0.003312239,0.0003108754,0.008415885,0.00006271149,0.00005168623,0.005453029],"genre_scores_gemma":[0.9902164,0.0004555643,0.001477598,0.001890957,0.0002942029,0.004276385,0.00003883708,0.00005637666,0.001293639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09215649,"threshold_uncertainty_score":0.6851054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1232492547322935,"score_gpt":0.4226656086118182,"score_spread":0.2994163538795246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}